FDA Brief

Warning letters Drugs

FDA warning letter to

Ultra Chem Labs Corporation

High riskIssued Dec 20, 2022Posted Feb 28, 2023Division of Pharmaceutical Quality Operations IV

FDA warns Ultra Chem Labs about methanol-tainted hand sanitizer sold as an unapproved, misbranded drug.

What happened

FDA inspected Ultra Chem Labs Corporation's drug manufacturing facility in Ontario, California, from July 25 to July 27, 2022. The agency found violations of Current Good Manufacturing Practice (CGMP), the rules for drug manufacturing, including that the quality unit approved an active ingredient, ULS 8357, that contained methanol and released hand sanitizer batches without determining finished-product methanol content. FDA also found the hand sanitizer was an unapproved new drug and misbranded because its label did not list methanol.

What FDA found

  1. The quality control unit approved ULS 8357, an active ingredient that contained methanol, for use without evaluating its suitability and released hand sanitizer batches without testing the finished product for methanol.

    21 CFR 211.22
  2. The firm did not perform adequate release testing, including identity, strength, and microbial testing, before releasing hand sanitizer batches.

    21 CFR 211.165(a) and 21 CFR 211.165(b)
  3. The firm did not test incoming components for identity, purity, strength, and quality and did not establish the reliability of supplier test results or obtain certificates of analysis.

    21 CFR 211.84(d)(1) and 21 CFR 211.84(d)(2)
  4. The hand sanitizer was an unapproved new drug because it was not generally recognized as safe and effective and did not meet the conditions for marketing without an approved application.

    FD&C Act section 505(a), 21 U.S.C. 355(a)
  5. The product was misbranded because it was dangerous to health when used as labeled, its labeling was false or misleading by not revealing methanol, it did not list methanol as an ingredient, and it did not comply with section 505G.

    FD&C Act sections 502(j), (a), (e)(1)(A), and (ee), 21 U.S.C. 352(j), (a), (e)(1)(A), and (ee)
  6. The quality unit also failed to have adequate procedures for investigations, deviations, complaints, and returns; adequate employee training; a stability program; reserve samples; and adequate batch production records.

    21 CFR 211.22(d), 211.25(a), 211.137(a), 211.170(b), 211.188

What FDA wants

FDA asks the company to respond in writing within 15 working days with what it has done to correct the violations and prevent recurrence. FDA also asks the company to clarify whether it intends to resume drug manufacturing and, if so, to engage a qualified CGMP consultant and notify FDA before resuming.

Who should pay attention

  • consumers who use hand sanitizers
  • retailers and distributors that sold Proton Armor hand sanitizer
  • OTC drug manufacturers and contract manufacturers that rely on supplier certificates of analysis

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. World Perfumes Inc.

    World Perfumes failed to test drug ingredients for toxic contaminants and had inadequate water, FDA says.

    High risk
  2. RNA Bio/Pharma, Incorporated

    FDA found RNA Bio/Pharma failed to test homeopathic oral liquid drugs for dangerous contaminants and did not validate its water system.

    High risk
  3. Kabana Skin Care LLC

    Kabana Skin Care failed to test OTC drug ingredients and finished products, prompting a recall and halt of U.S. drug manufacturing.

    High risk
  4. Ningbo Riway Industrial Co., Ltd.

    Ningbo Riway Industrial, an OTC drug maker in China, was cited for manufacturing-practice failures and unapproved antiseptic wipes.

    High risk